TherapeuticsMD (TXMD) Competitors $1.05 +0.04 (+3.96%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.02 -0.03 (-2.38%) As of 03/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TXMD vs. CVKD, GBIO, FBRX, MDCX, CASI, NRXP, ESLA, LVTX, XCUR, and INKTShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Cadrenal Therapeutics (CVKD), Generation Bio (GBIO), Forte Biosciences (FBRX), Medicus Pharma (MDCX), CASI Pharmaceuticals (CASI), NRx Pharmaceuticals (NRXP), Estrella Immunopharma (ESLA), LAVA Therapeutics (LVTX), Exicure (XCUR), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Cadrenal Therapeutics Generation Bio Forte Biosciences Medicus Pharma CASI Pharmaceuticals NRx Pharmaceuticals Estrella Immunopharma LAVA Therapeutics Exicure MiNK Therapeutics TherapeuticsMD (NASDAQ:TXMD) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings. Is TXMD or CVKD more profitable? Cadrenal Therapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-207.77% -14.08% -9.61% Cadrenal Therapeutics N/A -142.95%-118.40% Do insiders & institutionals have more ownership in TXMD or CVKD? 30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 2.3% of TherapeuticsMD shares are owned by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer TXMD or CVKD? TherapeuticsMD received 380 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 58.57% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformTherapeuticsMDOutperform Votes38658.57% Underperform Votes27341.43% Cadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo Votes Which has better earnings and valuation, TXMD or CVKD? Cadrenal Therapeutics has lower revenue, but higher earnings than TherapeuticsMD. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.60M7.59-$10.28MN/AN/ACadrenal TherapeuticsN/AN/A-$8.36M-$8.67-2.16 Does the media favor TXMD or CVKD? In the previous week, TherapeuticsMD had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for TherapeuticsMD and 2 mentions for Cadrenal Therapeutics. TherapeuticsMD's average media sentiment score of 0.72 beat Cadrenal Therapeutics' score of 0.44 indicating that TherapeuticsMD is being referred to more favorably in the media. Company Overall Sentiment TherapeuticsMD Positive Cadrenal Therapeutics Neutral Do analysts rate TXMD or CVKD? Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 71.03%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, TXMD or CVKD? TherapeuticsMD has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. SummaryCadrenal Therapeutics beats TherapeuticsMD on 8 of the 15 factors compared between the two stocks. Remove Ads Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.11M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E RatioN/A7.2023.1419.03Price / Sales7.59226.01384.1193.17Price / CashN/A65.6738.1634.64Price / Book0.386.476.954.33Net Income-$10.28M$141.90M$3.20B$247.06M7 Day Performance17.98%-3.20%-2.28%-0.37%1 Month Performance12.90%-5.64%2.88%-3.85%1 Year Performance-54.15%-7.47%10.87%1.27% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.9276 of 5 stars$1.05+4.0%N/A-53.3%$12.11M$1.60M0.00420Short Interest ↓News CoverageCVKDCadrenal Therapeutics2.6031 of 5 stars$19.87+4.1%$32.00+61.0%N/A$35.43MN/A-2.984Short Interest ↑GBIOGeneration Bio4.0017 of 5 stars$0.53+10.4%$7.33+1,283.6%-87.7%$35.40M$18.58M-0.24150Short Interest ↓Gap UpHigh Trading VolumeFBRXForte Biosciences3.0307 of 5 stars$5.52-4.8%$23.58+327.2%+28,357.3%$35.29MN/A-0.345MDCXMedicus PharmaN/A$2.95-10.3%$10.00+239.0%N/A$35.17MN/A0.00N/ACASICASI Pharmaceuticals4.352 of 5 stars$2.26+1.8%$6.00+165.5%-26.7%$35.01M$22.06M-1.01180Analyst ForecastShort Interest ↓Positive NewsNRXPNRx Pharmaceuticals2.6081 of 5 stars$2.05-12.8%$31.67+1,444.7%-96.1%$34.68MN/A-0.962ESLAEstrella Immunopharma2.4968 of 5 stars$0.96+4.0%$16.00+1,571.5%-25.8%$34.63MN/A-3.68N/AGap UpLVTXLAVA Therapeutics2.5804 of 5 stars$1.31+0.8%$3.17+141.7%-66.8%$34.45M$7.35M-1.2760Short Interest ↓XCURExicure1.276 of 5 stars$12.99+1.2%N/A+2,166.8%$33.85M$500,000.00-6.2850Short Interest ↑News CoverageGap UpINKTMiNK Therapeutics2.4505 of 5 stars$8.52+0.4%$37.50+340.1%+0.9%$33.77MN/A-2.1830Gap Up Remove Ads Related Companies and Tools Related Companies Cadrenal Therapeutics Alternatives Generation Bio Alternatives Forte Biosciences Alternatives Medicus Pharma Alternatives CASI Pharmaceuticals Alternatives NRx Pharmaceuticals Alternatives Estrella Immunopharma Alternatives LAVA Therapeutics Alternatives Exicure Alternatives MiNK Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXMD) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TXMD Stock Free TXMD Stock Alerts